BARDA Project BioShield Contract Awarded

December 18, 2019

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Agenda

Introduction
Ben Strain, Vice President, Investor Relations & Corporate Communications

Opening Remarks & Contract Overview
Evan Loh, M.D., Chief Executive Officer

Project BioShield RFP and Anthrax Data Overview
Randy Brenner, Chief Development & Regulatory Officer

Conclusion
Evan Loh, M.D., Chief Executive Officer

Q&A

Also available for Q&A:
Michael F. Bigham, Executive Chairman
Adam Woodrow, President and Chief Commercial Officer

PARATEK®

Safe Harbor Statement

Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The information contained in this presentation is accurate only as of the date hereof.

This presentation contains forward-looking statements including statements related to the Company's award and agreement with the Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), our future anticipated funding and activities and commitments under the award, the study of NUZYRA in new indications, our overall strategy, products, prospects and potential. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the new indications, plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2018 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

PARATEK®

Opening Remarks

Evan Loh, M.D.,
Chief Executive Officer

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

BARDA Project BioShield Contract Award
Valued up to $285 million to Paratek

Contract Provisions	Value	Timing
Base Award		
• **Development** of **NUZYRA**: **Treatment** of pulmonary **anthrax** • **Purchase** of an initial 2,500 treatment courses	~$21 million ~$38 million	• Funding period: **2020** through **2024** • 2500 treatment courses: **1H 2020**
Time-Based Options		
• FDA **post marketing requirements** including CABP and pediatric studies	~$77 million	• Funding to commence in **2Q 2020**
• **Manufacturing** security-related requirements	~$20 million	• Funding to commence in **2Q 2020**
Milestone-based Options		
• **Three additional purchases** of NUYZYRA for up to 7,500 treatment courses	~$115 million	• 2500 treatment courses: ~**2021** • 2500 treatment courses: ~**2022** • 2500 treatment courses: ~**2023**
• **Development** of **NUZYRA: Prophylaxis** of pulmonary **anthrax**	~$13 million	• Program to commence with funding: **~2022**

PARATEK®

PARATEK®

Project BioShield RFP & Anthrax Data Overview

Randy Brenner, Chief Development & Regulatory Officer

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Project BioShield RFP

NUZYRA Meets All Mandatory Requirements

1. An asset that is either late-stage in development for or approved with a pneumonic indication
2. Proven safe and effective to treat resistant pathogens
3. Proven or promising in vitro/in vivo activity against known biothreat pathogens
4. A developed and established manufacturing process for API and drug product
5. Ongoing stability program designed to achieve up to 5 years of shelf life
6. Eligible for Emergency Use Authorization (EUA) pre-approval by FDA for a biothreat indication

PARATEK

NUZYRA Published Data in Anthrax

Compelling in vitro Activity and in vivo Efficacy

In vitro activity



In vivo efficacy



Whole Body Aerosol *B. anthracis*
(Ames spores)
9.8 x LD50s
24h post-challenge (PEP)
MIC of OMC ≤0.03 µg/mL

- Antimicrobial Agents and Chemotherapy; May 2017
- ASM Biodefense; February 25-27, 2013

PARATEK®

PARATEK®

Conclusion

Evan Loh, M.D.,
Chief Executive Officer

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.